Type 1 Diabetes Mellitus Clinical Trials

18 studies are recruiting for type 1 diabetes mellitus in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Type 1 Diabetes Extension Study

   This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long…

   Stage

   Not phased

   Ages

   8 to 35

   Site

   UCSF School of Medicine, San Francisco, California

   Locations

   12 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT02734277 on ClinicalTrials.gov

2. A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

   This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenou…

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Scottsdale Clinical Trials- Site Number : 8400044, Scottsdale, Arizona

   Locations

   197 in total

   Run by

   Sanofi

   See if you can join NCT07088068 on ClinicalTrials.gov

3. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   Wake Research - Tucson, Tucson, Arizona

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

4. Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

   This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will then be followed for at least 12-48 months a…

   Stage

   Phase 2

   Ages

   4 to 34

   Site

   Barbara Davis Center, Aurora, Colorado

   Locations

   6 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07216391 on ClinicalTrials.gov

5. Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

   This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once eve…

   Stage

   Phase 2

   Ages

   8 to 45

   Site

   University of California San Francisco, San Francisco, California

   Locations

   15 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07142252 on ClinicalTrials.gov

6. A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

   This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 D…

   Stage

   Phase 1

   Ages

   35 to 70

   Site

   University of Illinois Hospital & Health Sciences System, Chicago, Illinois

   Run by

   Otsuka Pharmaceutical Factory, Inc.

   See if you can join NCT06575426 on ClinicalTrials.gov

7. INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

   INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to <18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of …

   Stage

   Phase 2

   Ages

   6 to 17

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   10 in total

   Run by

   Mannkind Corporation

   See if you can join NCT07224321 on ClinicalTrials.gov

8. A Study of GNTI-122 in Adults Recently Diagnosed With T1D

   This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnose…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   10 in total

   Run by

   GentiBio, Inc

   See if you can join NCT06919354 on ClinicalTrials.gov

9. Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

   This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

   Stage

   Not phased

   Ages

   14 to 75

   Site

   University of Southern California, Los Angeles, California

   Locations

   11 in total

   Run by

   Insulet Corporation

   See if you can join NCT07579702 on ClinicalTrials.gov

10. A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers

    The investigators will assess both effectiveness (primary) and implementation (secondary) outcomes for a distress-reducing intervention, Supporting Teen Problem Solving (STePS). STePS has already undergone an efficacy trial. The current study allows for evaluating the outcomes of STePS by deliverin…

    Stage

    Not phased

    Ages

    14 to 18

    Site

    Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois

    Run by

    Jill Weissberg-Benchell, Ph.D.

    See if you can join NCT06709755 on ClinicalTrials.gov

11. Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

    This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1 diabetes.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Diablo Clinical Research, Walnut Creek, California

    Locations

    4 in total

    Run by

    i-SENS, Inc.

    See if you can join NCT07296276 on ClinicalTrials.gov

12. Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

    This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Diabetes Research Institute, Miami, Florida

    Run by

    Rodolfo Alejandro

    See if you can join NCT01999361 on ClinicalTrials.gov

13. Long Term Follow up of Recipients of Functional Islet Allografts

    Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a …

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Diabetes Research Institute, Miami, Florida

    Run by

    Rodolfo Alejandro

    See if you can join NCT01999374 on ClinicalTrials.gov

14. Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss

    This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.

    Stage

    Not phased

    Ages

    18 to 75

    Site

    Diabetes Research Institute, Miami, Florida

    Run by

    Rodolfo Alejandro

    See if you can join NCT02000687 on ClinicalTrials.gov

15. Twiist Postmarket Surveillance Study for Type 1 Diabetes

    The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.

    Stage

    Not phased

    Ages

    6 and older

    Site

    Jaeb Center for Health Research, Tampa, Florida

    Run by

    Deka Research and Development

    See if you can join NCT07356089 on ClinicalTrials.gov

16. Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

    This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GC…

    Stage

    EARLY_Phase 1

    Ages

    18 to 60

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT06609356 on ClinicalTrials.gov

17. The Effects of Fluoxetine and/or DHEA

    (1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), sti…

    Stage

    EARLY_Phase 1

    Ages

    18 to 50

    Site

    University of Maryland, Baltimore, Maryland

    Run by

    University of Maryland, Baltimore

    See if you can join NCT03228732 on ClinicalTrials.gov

18. Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

    The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2, mild to moderate, neuroischemic diabetic chronic foot ulcers in subjects…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    WoundCentrics Wound Care & Hyperbarics -Corpus Christi - Shoreline, Corpus Christi, Texas

    Locations

    2 in total

    Run by

    Estar Medical dba Medical Technologies, LTD

    See if you can join NCT06810726 on ClinicalTrials.gov